Lv72
3790 积分 2023-05-31 加入
Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma
1小时前
待确认
Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type
1小时前
待确认
Benefit of Consolidative Radiation Therapy in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP Chemotherapy
3小时前
待确认
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study
3小时前
待确认
Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era
3小时前
待确认
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
3小时前
待确认
Rituximab in treatment of primary gastric diffuse large B-cell lymphoma
19小时前
待确认
Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan
19小时前
待确认
The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma
19小时前
待确认
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP
20小时前
待确认
皖公网安备34019202002308
